AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 131 min read$BBIO

Ellis Andrea sold $1.4M of BBIO

Ellis Andrea sold 17,167 shares of BridgeBio Pharma, Inc. (BBIO) at $84.00 ($1.44M total) on 2026-07-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Ellis Andrea
Published Jul 13, 2026, 8:41 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 13, 2026, 8:43 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$BBIO
Neutral
high confidence
Mentioned
$BBIO
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BBIONeutralLow
01

Why it matters

The newest concrete fact is the director’s open-market sale details and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Insider selling can affect short-term sentiment, but 10b5-1 plans generally reduce interpretive value for fundamentals.

03

What to watch

Traders may still watch for follow-on insider activity or unusual volume around the filing date, but this article alone does not provide that.

Relevance 5/10Novelty 3/10Timing: Filed 2026-07-13 after-hours; reflects sale executed 2026-07-09.

Background

The article is an SEC Form 4 insider transaction disclosure for BridgeBio Pharma, Inc.

Company-level read

Ticker impact

$BBIONeutralHigh confidence
Context

BridgeBio director Ellis Andrea sold 17,167 shares at $84.00 on 2026-07-09 under a pre-arranged 10b5-1 plan, totaling $1.44M.

Expected impact

Likely limited near-term impact; any effect would be sentiment-only and typically fades as a 10b5-1 sale.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new company fundamentals or guidance.

Market effects

Sector

No direct sector read-through; this is company-specific insider liquidity activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because it is a 10b5-1 plan, the sale may be purely scheduled liquidity rather than a bearish signal.

Key entities

  • issuer
    BridgeBio Pharma, Inc.

    Subject of the Form 4 insider sale disclosure.

  • insider
    Ellis Andrea

    Director who sold 17,167 shares on 2026-07-09.

Read at source← All news

Related articles

JUL 23
$BBIOMedAI 8/10

FDA Accepts BridgeBio's Filing for Rare Genetic Disease Drug

BridgeBio Pharma (BBIO) said the FDA accepted its filing for encaleret, an oral investigational drug for autosomal dominant hypocalcemia type 1 (ADH1). A decision is expected by May 8, 2027. The company cited phase III CALIBRATE results and noted the FDA is not planning an advisory committee meeting. BBIO shares are up 8% YTD.

tradingview.com4 min
JUL 22
$BBIOMedAI 8/10

FDA accepts BridgeBio's NDA for encaleret to tr... | Pluang

BridgeBio Pharma said the FDA accepted its New Drug Application for encaleret, intended as a potential first treatment for autosomal dominant hypocalcemia type 1 (ADH1). The FDA target decision date is May 8, 2027. BridgeBio cited trial results showing efficacy and safety without routine calcium or vitamin D supplements, and is also studying pediatric ADH1 and chronic hypoparathyroidism.

pluang.com1 min
JUL 21
$AZNMed

Biotech and Pharma Industry News | BioPharma Dive

BioPharma Dive roundup covers AstraZeneca’s eplontersen failure in a major heart disease study, boosting expectations for rival TTR amyloidosis drugs from Alnylam and BridgeBio. Other items include ARPA-H funding, GSK ending a neuroscience alliance with Alector, Vera Therapeutics’ FDA nod for IgA nephropathy, and Vertex’s $10B plan to buy Crinetics.

biopharmadive.com7 min
JUL 10
$BBIOMedAI 8/10

BridgeBio stock jumps after rival heart drug fails key trial

BridgeBio (BBIO) shares rose 14.7% on July 9 after AstraZeneca and Ionis said their Wainua (eplontersen) failed the primary endpoint in a Phase 3 CARDIO-TTRansform trial for ATTR-CM. The study enrolled 1,432 patients. BridgeBio was trading around $89.86, adding about $2.2B in market value intraday.

yahoo.com4 min
JUL 9
$AZNHighAI 9/10

Gene-Silencing Drug Wainua Fails Landmark ATTR-CM Trial in AstraZeneca Setback

AstraZeneca and Ionis said their gene-silencing drug Wainua (eplontersen) failed the Phase 3 CARDIO-TTRansform trial in transthyretin-mediated amyloid cardiomyopathy. The study enrolled 1,432 patients over 140 weeks and did not significantly reduce cardiovascular deaths or recurrent events vs placebo. AstraZeneca shares fell about 9% and Ionis about 21%.

techtimes.com7 min